title: MiR-125b regulates epithelial-mesenchymal transition via targeting Sema4C in paclitaxel-resistant breast cancer cells.
abstract: Emerging evidence has demonstrated that microRNAs (miRNA) play a critical role in chemotherapy-induced epithelial-mesenchymal transition (EMT) in breast cancer. However, the underlying mechanism of chemotherapy-mediated EMT has not been fully understood. To address this concern, we explored the role of miR-125b in regulation of EMT in stable paclitaxel-resistant (PR) breast cancer cells, namely MCF-7 PR and SKBR3 PR, which have displayed mesenchymal features. Our results illustrated that miR-125b was significantly downregulated in PR cells. Moreover, ectopic expression of miR-125b by its mimics reversed the phenotype of EMT in PR cells. Furthermore, we found that miR-125b governed PR-mediate EMT partly due to governing its target Sema4C. More importantly, overexpression of miR-125b or depletion of Sema4C sensitized PR cells to paclitaxel. These findings suggest that up-regulation of miR-125b or targeting Sema4C could serve as novel approaches to reverse chemotherapy resistance in breast cancers.
authors.affiliation: Department of Biochemistry and Molecular Biology, Bengbu Medical College, Anhui, China.
authors.forename: Qingling
authors.initials: Q
authors.lastname: Yang
authors.affiliation: Clinical Testing and Diagnose Experimental Center of Bengbu Medical College, Anhui, China.
authors.forename: Yangyang
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Clinical Testing and Diagnose Experimental Center of Bengbu Medical College, Anhui, China.
authors.forename: Xiaohui
authors.initials: X
authors.lastname: Lu
authors.affiliation: Clinical Testing and Diagnose Experimental Center of Bengbu Medical College, Anhui, China.
authors.forename: Zunlan
authors.initials: Z
authors.lastname: Zhao
authors.affiliation: Clinical Testing and Diagnose Experimental Center of Bengbu Medical College, Anhui, China.
authors.forename: Lihua
authors.initials: L
authors.lastname: Zhu
authors.affiliation: Department of Biochemistry and Molecular Biology, Bengbu Medical College, Anhui, China.
authors.forename: Sulian
authors.initials: S
authors.lastname: Chen
authors.affiliation: Department of Medical Oncology, First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
authors.forename: Qiong
authors.initials: Q
authors.lastname: Wu
authors.affiliation: Department of Biochemistry and Molecular Biology, Bengbu Medical College, Anhui, China.
authors.forename: Changjie
authors.initials: C
authors.lastname: Chen
authors.affiliation: Cyrus Tang Hematology Center, Jiangsu Institute of Hematology, Collaborative Innovation Center of Hematology, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
authors.forename: Zhiwei
authors.initials: Z
authors.lastname: Wang
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D002465:Cell Movement; D019008:Drug Resistance, Neoplasm; D058750:Epithelial-Mesenchymal Transition / Q000187:drug effects*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D061986:MCF-7 Cells; D035683:MicroRNAs / Q000235:genetics / Q000378:metabolism*; D009361:Neoplasm Invasiveness; D017239:Paclitaxel / Q000494:pharmacology*; D034622:RNA Interference; D039961:Semaphorins / Q000235:genetics / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects; D014162:Transfection
chemical_list: D000970:Antineoplastic Agents; C531888:MIRN125 microRNA, human; D035683:MicroRNAs; C000592635:Sema4c protein, human; D039961:Semaphorins; D017239:Paclitaxel